Aromatase inhibitors inhibit the aromatase enzyme, which turns androgens into estrogen. This reduction in estrogen effectively hinders the growth signal for ER+ cancer cells, leading to improved clinical trial outcomes and lower recurrence rates. This evidence concerns the gene ESR1 and cancer.